DGAP-News: Epigenomics AG / Key word(s): Quarterly / Interim Statement/Quarter Results10.11.2021 / 08:00 The issuer is solely responsible for the content of this announcement. Epigenomics AG publishes financial results for the first nine months 2021 Berlin (Germany) and San Diego, CA (U.S.A.), November 10, 2021 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the “Company”) today […]
Category: Press Releases
10. November 2021
Epigenomics AG publishes financial results for the first nine months 2021
Read more
07. October 2021
Epigenomics AG: EVP of Finance Albert Weber leaves the Company
DGAP-News: Epigenomics AG / Key word(s): Personnel07.10.2021 / 08:00 The issuer is solely responsible for the content of this announcement. Epigenomics AG: EVP of Finance Albert Weber leaves the Company Berlin (Germany) and San Diego, CA (U.S.A.), October 7, 2021 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “Company”) announces that Executive Vice […]
13. September 2021
Epigenomics AG places maximum number of mandatory convertible bonds with a total volume of EUR 16.5 million
DGAP-News: Epigenomics AG / Key word(s): Bond/Issue of Debt13.09.2021 / 13:24 The issuer is solely responsible for the content of this announcement. NOT TO BE PUBLISHED, DISSEMINATED OR PASSED ON TO OR WITHIN THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA AND SOUTH AFRICA Press Release Epigenomics AG places maximum number of mandatory convertible bonds […]
02. September 2021
New study in the BMC Cancer journal shows that Epi proColon(R) is an effective method to increase CRC screening rates in medically underserved populations
DGAP-News: Epigenomics AG / Key word(s): Study results/Study02.09.2021 / 13:42 The issuer is solely responsible for the content of this announcement. New study in the BMC Cancer journal shows that Epi proColon(R) is an effective method to increase CRC screening rates in medically underserved populations The availability of blood based mSEPT9 tests, such as Epi […]
24. August 2021
Epigenomics AG: Securities prospectus for the issuance of a mandatory convertible bond in the amount of up to EUR 16.5 million approved by BaFin
DGAP-News: Epigenomics AG / Key word(s): Issue of Debt/Corporate Action24.08.2021 / 16:16 The issuer is solely responsible for the content of this announcement. NOT TO BE PUBLISHED, DISSEMINATED OR PASSED ON TO OR WITHIN THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA AND SOUTH AFRICA Press Release / Advertising Epigenomics AG: Securities prospectus for the […]
11. August 2021
Epigenomics AG Reports Financial Results for the First Six Months of 2021
DGAP-News: Epigenomics AG / Key word(s): Half Year Report/Half Year Results11.08.2021 / 08:00 The issuer is solely responsible for the content of this announcement. Epigenomics AG Reports Financial Results for the First Six Months of 2021 Berlin (Germany) and San Diego, CA (U.S.A.), August 11, 2021 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the “Company”) […]